An anti-COVID-19 therapeutic drug developed by DRDO called drug2-deoxy-D-glucose (2-DG) has been given emergency approval by the Drug Controller General of India (DCGI) for Coronavirus patients in the country. The Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of Defence Research and Development Organisation (DRDO), has developed the drug, in collaboration with Dr Reddy’s Laboratories, Hyderabad.
Buy Prime Test Series for all Banking, SSC, Insurance & other exams
In 2-DG arm, significantly higher proportion of patients improved symptomatically and became free from supplemental oxygen dependence (42% vs 31%) by day-3 in comparison to SOC, indicating an early relief from oxygen therapy/dependence. The drug comes in the form of a powder in a sachet & is supposed to be dissolved in water.
Important takeaways for all competitive exams:
Goa is a small state on the western coast of India, famous for its beaches,…
Every year, people around the world search for words that show what interests them the…
The Hurun Rich List 2025 has once again highlighted India’s dynamic startup and business ecosystem.…
India’s innovation ecosystem has received global recognition as an Indian satellite internet concept emerged as…
India’s fiscal position showed resilience in the current financial year as net direct tax collections…
Recently, the Union Minister informed the Rajya Sabha about the progress and impact of the…